Questions
Ipamorelin FAQ
Direct, cited answers to the questions people actually ask about ipamorelin.
Does ipamorelin reduce belly fat?
No human study has measured ipamorelin against belly fat. The most relevant recent data is a 2024 ferret study where ipamorelin (1–3 mg/kg) cut chemotherapy-induced body-weight loss by about 24% — a weight-protective effect during wasting, not a fat-loss effect [5]. Community reports of gradual leaning are anecdotal and confounded by diet and training.
Is there new research on ipamorelin in 2024?
Yes. The most recent in-vivo study is a 2024 ferret experiment in which intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by roughly 24% in the delayed phase, with no anti-emetic effect [5]. A 2024 study also found the related ghrelin system protects aging muscle [7]. Several 2026 narrative reviews then summarized ipamorelin as investigational [14][15].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor (GHS-R1a) to release growth hormone [1]. In its founding study it released growth hormone potently in rats and swine (swine ED50 = 2.3 nmol/kg) without raising cortisol or prolactin — the selectivity that made it the first 'selective' growth hormone secretagogue [1]. It is not an approved drug.
What does ipamorelin do for you?
In research terms, ipamorelin triggers a discrete pulse of growth hormone by activating the ghrelin receptor on pituitary cells, doing so without the cortisol or prolactin spillover of older peptides [1]. It is not approved for any human use, and its only Phase 2 human trial missed its endpoint [3]. Reported effects in the community — sleep, recovery — are anecdotal, not clinical findings.
What is ipamorelin peptide?
Ipamorelin peptide is a wholly synthetic five-amino-acid chain (a pentapeptide) engineered to mimic ghrelin at the GHS-R1a receptor [1]. It uses non-natural amino acids that resist enzyme breakdown, and it was derived from GHRP-1. Its signature property is selectivity: strong growth-hormone release with minimal cortisol and prolactin effect [1]. It is sold only as a research chemical.
What are the risks of ipamorelin?
The documented risk is the absence of evidence: the only Phase 2 RCT (n=114, up to 7 days IV) missed its endpoint and showed no specific safety signal in that short window [3], but there is no long-term human safety data. A class-level concern comes from a 28-day rat study of a related ghrelin-receptor agonist that found heart-muscle degeneration [6]. Mechanistic cautions involve blood sugar and IGF-1 [11][1].
What are the downsides of ipamorelin?
The biggest downside is unproven efficacy: the one controlled human trial (postoperative ileus, 0.03 mg/kg IV twice daily) did not beat placebo (25.3 h vs 32.6 h, p = 0.15) [3]. Beyond that, no Phase 3 exists, long-term safety is uncharacterized, and most material is unregulated research-grade of unverified purity. Community-reported nuisances include flushing, water retention, and increased hunger.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product, so it is not being 'discontinued' in the usual sense — its clinical development stopped after its only Phase 2 trial for postoperative ileus missed its primary endpoint [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access, which some read as a withdrawal.
What does CJC-1295 and ipamorelin do?
Together they raise growth hormone through two different receptors: CJC-1295 (a GHRH analog) via the GHRH receptor and ipamorelin via the ghrelin receptor [1], so their effects are additive. A 2026 orthopaedic review reported the pair improved maximum muscle tetanic tension in a glucocorticoid muscle-loss model in mice, while emphasizing the evidence is animal-only [14]. No human trial has tested the combination.
Does ipamorelin increase IGF-1?
Not reliably in short studies. Ipamorelin releases growth hormone, and growth hormone normally drives IGF-1, but in a 15-day rat bone-growth study ipamorelin raised bone growth without changing total IGF-1 [4]. IGF-1 does rise in some combination and longer protocols — for example, ipamorelin plus a glucocorticoid raised IGF-1 in rats [8] — so the effect is context-dependent.
How does CJC-1295 ipamorelin work?
Each component presses a different button. CJC-1295 activates the GHRH receptor; ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary cells, releasing a calcium-driven growth-hormone pulse [1]. Because the two receptors trigger growth-hormone release by separate, complementary pathways, combining them is meant to produce a larger pulse than either alone — though this rationale rests on single-agent pharmacology, not a combination trial [14].
How much CJC-1295 ipamorelin should I take?
This site does not provide a dose, and no evidence-based human dosing protocol exists. The only human ipamorelin doses on record are IV research figures (4.21–140.45 nmol/kg single doses; 0.03 mg/kg IV twice daily in the trial) [2][3], not subcutaneous self-administration regimens. The CJC-1295 combination has no human trial of any dose for any outcome [14], so circulating community protocols are anecdotal, not recommendations.
Does CJC-1295 ipamorelin work?
In animals and mechanistically, there are real signals — a 2026 review reported improved maximum tetanic tension in a murine muscle-loss model [14], and single-agent rodent studies show genuine growth-hormone release [1]. In controlled human outcome terms there is no evidence either way: the combination has never been tested in a human trial, and ipamorelin's lone human efficacy trial missed its endpoint [3].
How to reconstitute CJC-1295 ipamorelin 5mg?
The research-supply literature describes ipamorelin as a lyophilized (freeze-dried) powder reconstituted with bacteriostatic water for research handling, kept refrigerated because peptides degrade with heat and freeze-thaw. These are general handling notes, not a clinical preparation instruction. Note the human pharmacokinetics on record — a ~2 h half-life — were measured for IV administration [2], not for reconstituted subcutaneous mixtures.
How long does ipamorelin stay in your system?
Ipamorelin's terminal half-life is about 2 hours in healthy human volunteers given IV infusions, with clearance of 0.078 L/h/kg [2]. Because roughly four to five half-lives clear most of a dose, the molecule itself is largely gone within about 8–10 hours. The growth-hormone pulse it triggers is briefer still, peaking around 40 minutes after dosing as a single discrete pulse [2].
Does ipamorelin make you hungry?
It can, by mechanism. Ipamorelin acts on the ghrelin receptor — the same receptor the body's natural hunger hormone uses — and ghrelin-receptor agonists activate the brain's appetite centers [13]. Community reports describe increased hunger in the hours after injection, generally milder than with GHRP-6 [12]. This is the most mechanistically expected of its anecdotal effects, though it is not universal.
Will I gain weight on ipamorelin?
There is no human weight data at research-use doses. Mechanistically, ipamorelin stimulated adiposity and raised leptin in mice independently of growth hormone [12], and it can increase appetite via the ghrelin receptor [13] — both of which point toward weight gain in some settings. Counterintuitively, in a 2024 ferret cachexia model it protected against weight loss [5]. Net human effect is unknown.
Does ipamorelin increase appetite?
Yes, by its mechanism. As a ghrelin-receptor agonist, ipamorelin acts on the same system that drives hunger, and central ghrelin-receptor activation induces feeding [13]. In mice it raised adiposity and leptin independently of growth hormone [12]. Community accounts report increased hunger after injection, described as milder than with GHRP-6 but still unwanted for some users managing intake.
What does ipamorelin peptide do?
Ipamorelin peptide activates the ghrelin receptor (GHS-R1a) on pituitary cells to release a discrete pulse of growth hormone, doing so selectively — without raising cortisol or prolactin meaningfully [1]. It also has peripheral actions, including direct insulin release from rat pancreatic tissue [11]. It is investigational only; its single Phase 2 human trial missed its endpoint [3], and it is not approved anywhere.
How long does it take for ipamorelin to work?
Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes (0.67 h) after an IV dose in humans [2]. Subjectively, community reports of effects like deeper sleep often describe a one-to-two-week onset, but those are anecdotal and unverified, not measured outcomes. The measurable biology is immediate; any subjective 'working' timeline is a community report, not a study result.
Does ipamorelin cause water retention?
Mild water retention is occasionally reported by users, typically as transient puffiness in fingers, ankles, or face in the first two to four weeks, often described as milder than with older peptides. This fits the growth-hormone mechanism — growth-hormone excess is associated with sodium and water retention — but it is an anecdotal community observation here [3], not a measured outcome in any ipamorelin trial.
Where to inject CJC-1295 ipamorelin?
This site does not give administration instructions. For context, the human pharmacokinetic and clinical data for ipamorelin were generated by intravenous infusion [2], while the dominant route in community use is subcutaneous self-injection — which has no published human safety or pharmacokinetic characterization. The CJC-1295 combination has no human trial defining any route or site [14], so community injection-site practices are anecdotal, not evidence-based guidance.